Adaptimmune Therapeutics Plc (ADAP)
$0.63 -$0.00 (-0.36%) 4:38 PM 12/12/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$168.40M -
Day's Range
$0.61 - $0.65 -
Volume
1,956,052 -
52 Week Low / High
$0.43 - $2.05 -
PE Ratio
- -
PEG Ratio
0.11 -
Dividend Frequency
-
ADAP's Dividend
Hypothetical 10k Investment Jan 1, 2020
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
Analyists Ranking
- 4
- Strong Buy
- 2
- Buy
- 2
- Hold
- 1
- Sell
- 0
- Strong Sell
- $5.58
- Target Price
Company News
-
ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload — Aug 12th, 2024
By Michael Kim NASDAQ:ADAP READ THE FULL ADAP RESEARCH REPORT Pre-market open on 8/12/24, Adaptimmune (NASDAQ:ADAP) reported 2Q24 earnings results. ADAP reported net profit of $69.5 million for 2Q24, or $0.04 per diluted ordinary share compared to a net loss of $21.4 million, or ($0.02)...
|
Portfolio
$5,000/year
Goal: $10,000/year
Comprised of 1 portfolios
$